Immune checkpoint inhibitors in sarcomas: a systematic reviewΜaria Anastasiou, Amanda Psyrri, Anastasios Kyriazoglou et al.|Immuno-Oncology Technology|2023Cited by 21
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasmsAnastasios Kyriazoglou, Amanda Psyrri, Myrto Moutafi et al.|Cancer Treatment Reviews|2024Cited by 9
Real World Data from Patients With Osteosarcoma Treated in 8 Medical Centers in Greece: Ninety Percent or Greater Tumor Necrosis Is Associated With Disease‐free SurvivalAnastasios Kyriazoglou, Ioannis Boukovinas, Myrto Moutafi et al.|Cancer Diagnosis & Prognosis|2025Cited by 1
Immune‑mediated liver injury caused by checkpoint inhibitors: A case series and review of the literatureMaria Kyrkasiadou, Amanda Psyrri, Anastasios Kyriazoglou et al.|Experimental and Therapeutic Medicine|2026Cited by 0
Screening of TROP2, Nectin-4, and HER2 in osteosarcomas: In pursuit of a target.Anna Boulouta, Anastasios Kyriazoglou, Panagiota Economopoulou et al.|Journal of Clinical Oncology|2025Cited by 0